Court Orders FDA to Resolve Vanda Pharmaceuticals’ Jet Lag Hearing Request by March 5, 2024

January 29, 2024

https://www.prnewswire.com/news-releases/court-orders-fda-to-resolve-vanda-pharmaceuticals-jet-lag-hearing-request-by-march-5-2024-302047271.html

WASHINGTON, Jan. 29, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the United States District Court for the District of Columbia granted Vanda’s motion for summary judgment on its claim against the United States Food and Drug Administration (FDA) for unlawfully delaying a hearing on the approvability of Vanda’s supplemental new drug application (sNDA) for HETLIOZ® to treat jet lag disorder (Vanda Pharmaceuticals Inc. v. FDA, case no. 1:22-cv-2275-CJN).

Read more at prnewswire.com

Related news for (VNDA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.